Non‐traditional biomarkers of atherosclerosis in stable and unstable coronary artery disease, do they differ?

References

• Ross R. Atherosclerosis—an inflammatory disease. N Engl J Med 1999; 340: 115–26
   PubMed Web of Science ®Google Scholar
• Blankenberg S., Rupprecht H. J., Poirier O., Bickel C., Smieja M., Hafner G., et al. Plasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease. Circulation 2003; 107: 1579–85
   PubMed Web of Science ®Google Scholar
• Berdowska A., Zwirska‐Korczala K. Neopterin measurement in clinical diagnosis. J Clin Pharm Ther 2001; 26: 319–29
   PubMed Web of Science ®Google Scholar
• Brennan M. L., Penn M. S., Van Lente F., Nambi V., Shishehbor M. H., Aviles R. J., et al. Prognostic value of myeloperoxidase in patients with chest pain. N Engl J Med 2003; 349: 1595–604
   PubMed Web of Science ®Google Scholar
• Malarstig A., Tenno T., Johnston N., Lagerqvist B., Axelsson T., Syvanen A. C., et al. Genetic variations in the tissue factor gene are associated with clinical outcome in acute coronary syndrome and expression levels in human monocytes. Arterioscler Thromb Vasc Biol 2005; 25: 2667–72
   PubMed Web of Science ®Google Scholar
• Aikawa M., Libby P. The vulnerable atherosclerotic plaque: pathogenesis and therapeutic approach. Cardiovasc Pathol 2004; 13: 125–38
   PubMed Web of Science ®Google Scholar
• Virmani R., Burke A. P., Farb A., Kolodgie F. D. Pathology of the vulnerable plaque. J Am Coll Cardiol 2006; 47(Suppl.): C13–8
   Web of Science ®Google Scholar
• Aukrust P., Berge R. K., Ueland T., Aaser E., Damas J. K., Wikeby L., et al. Interaction between chemokines and oxidative stress: possible pathogenic role in acute coronary syndromes. J Am Coll Cardiol 2001; 37: 485–91
   PubMed Web of Science ®Google Scholar
• Mazzone A., De Servi S., Mazzucchelli I., Bossi I., Ottini E., Vezzoli M., et al. Increased concentrations of inflammatory mediators in unstable angina: correlation with serum troponin T. Heart 2001; 85: 571–5
   PubMed Web of Science ®Google Scholar
• Hojo Y., Ikeda U., Takahashi M., Shimada K. Increased levels of monocyte‐related cytokines in patients with unstable angina. Atherosclerosis 2002; 161: 403–8
   PubMed Web of Science ®Google Scholar
• Oshima S., Ogawa H., Hokimoto S., Nakamura S., Noda K., Saito T., et al. Plasma monocyte chemoattractant protein‐1 antigen levels and the risk of restenosis after coronary stent implantation. Jpn Circ J 2001; 65: 261–4
   PubMedGoogle Scholar
• Rothenbacher D., Muller‐Scholze S., Herder C., Koenig W., Kolb H. Differential expression of chemokines, risk of stable coronary heart disease, and correlation with established cardiovascular risk markers. Arterioscler Thromb Vasc Biol 2006; 26: 194–9
   PubMed Web of Science ®Google Scholar
• Haim M., Tanne D., Boyko V., Reshef T., Goldbourt U., Battler A., et al. Monocyte chemoattractant protein‐1 and recurrent cardiovascular events in patients with stable coronary heart disease. Clin Cardiol 2005; 28: 31–5
   PubMed Web of Science ®Google Scholar
• de Lemos J. A., Morrow D. A., Sabatine M. S., Murphy S. A., Gibson C. M., Antman E. M., et al. Association between plasma levels of monocyte chemoattractant protein‐1 and long‐term clinical outcomes in patients with acute coronary syndromes. Circulation 2003; 107: 690–5
   PubMed Web of Science ®Google Scholar
• Schumacher M., Halwachs G., Tatzber F., Fruhwald F. M., Zweiker R., Watzinger N., et al. Increased neopterin in patients with chronic and acute coronary syndromes. J Am Coll Cardiol 1997; 30: 703–7
   PubMed Web of Science ®Google Scholar
• Auer J., Berent R., Labetanig E., Eber B. Serum neopterin and activity of coronary artery disease. Heart Dis 2001; 3: 297–301
   PubMedGoogle Scholar
• Garcia‐Moll X., Cole D., Zouridakis E., Kaski J. C. Increased serum neopterin: a marker of coronary artery disease activity in women. Heart 2000; 83: 346–50
   PubMed Web of Science ®Google Scholar
• Avanzas P., Arroyo‐Espliguero R., Quiles J., Roy D., Kaski J. C. Elevated serum neopterin predicts future adverse cardiac events in patients with chronic stable angina pectoris. Eur Heart J 2005; 26: 457–63
   PubMed Web of Science ®Google Scholar
• Ilhan F., Akbulut H., Karaca I., Godekmerdan A., Ilkay E., Bulut V. Procalcitonin, c‐reactive protein and neopterin levels in patients with coronary atherosclerosis. Acta Cardiol 2005; 60: 361–5
   PubMed Web of Science ®Google Scholar
• Gupta S., Fredericks S., Schwartzman R. A., Holt D. W., Kaski J. C. Serum neopterin in acute coronary syndromes. Lancet 1997; 349: 1252–3
   PubMed Web of Science ®Google Scholar
• Auer J., Berent R., Lassnig E., Weber T., Eber B. Prognostic significance of immune activation after acute coronary syndromes. J Am Coll Cardiol 2002; 39((11))1878
   PubMed Web of Science ®Google Scholar
• van Haelst P. L., Liem A., van Boven A. J., Veeger N. J., van Veldhuisen D. J., Tervaert J. W., et al. Usefulness of elevated neopterin and C‐reactive protein levels in predicting cardiovascular events in patients with non‐Q‐wave myocardial infarction. Am J Cardiol 2003; 92: 1201–3
   PubMed Web of Science ®Google Scholar
• Dominguez‐Rodriguez A., Abreu‐Gonzalez P., Garcia‐Gonzalez M. Usefulness of neopterin levels and left ventricular function for risk assessment in survivors of acute myocardial infarction. Int J Cardiol 2006; 111: 318–20
   PubMed Web of Science ®Google Scholar
• Zhang R., Brennan M. L., Fu X., Aviles R. J., Pearce G. L., Penn M. S., et al. Association between myeloperoxidase levels and risk of coronary artery disease. JAMA 2001; 286: 2136–42
   PubMed Web of Science ®Google Scholar
• Jaremo P., Hansson G., Nilsson O. Elevated inflammatory parameters are associated with lower platelet density in acute myocardial infarctions with ST‐elevation. Thromb Res 2000; 100: 471–8
   PubMed Web of Science ®Google Scholar
• Baldus S., Heitzer T., Eiserich J. P., Lau D., Mollnau H., Ortak M., et al. Myeloperoxidase enhances nitric oxide catabolism during myocardial ischemia and reperfusion. Free Radic Biol Med 2004; 37: 902–11
   PubMed Web of Science ®Google Scholar
• Baldus S., Heeschen C., Meinertz T., Zeiher A. M., Eiserich J. P., Munzel T., et al. Myeloperoxidase serum levels predict risk in patients with acute coronary syndromes. Circulation 2003; 108: 1440–5
   PubMed Web of Science ®Google Scholar
• Kai H., Ikeda H., Yasukawa H., Kai M., Seki Y., Kuwahara F., et al. Peripheral blood levels of matrix metalloproteases‐2 and ‐9 are elevated in patients with acute coronary syndromes. J Am Coll Cardiol 1998; 32: 368–72
   PubMed Web of Science ®Google Scholar
• Tayebjee M. H., Lip G. Y., Tan K. T., Patel J. V., Hughes E. A., MacFadyen R. J. Plasma matrix metalloproteinase‐9, tissue inhibitor of metalloproteinase‐2, and CD40 ligand levels in patients with stable coronary artery disease. Am J Cardiol 2005; 96: 339–45
   PubMed Web of Science ®Google Scholar
• Zeng B., Prasan A., Fung K. C., Solanki V., Bruce D., Freedman S. B., et al. Elevated circulating levels of matrix metalloproteinase‐9 and ‐2 in patients with symptomatic coronary artery disease. Intern Med J 2005; 35: 331–5
   PubMed Web of Science ®Google Scholar
• Squire I. B., Evans J., Ng L. L., Loftus I. M., Thompson M. M. Plasma MMP‐9 and MMP‐2 following acute myocardial infarction in man: correlation with echocardiographic and neurohumoral parameters of left ventricular dysfunction. J Card Fail 2004; 10: 328–33
   PubMed Web of Science ®Google Scholar
• Tziakas D. N., Chalikias G. K., Parissis J. T., Hatzinikolaou E. I., Papadopoulos E. D., Tripsiannis G. A., et al. Serum profiles of matrix metalloproteinases and their tissue inhibitor in patients with acute coronary syndromes. The effects of short‐term atorvastatin administration. Int J Cardiol 2004; 94: 269–77
   PubMed Web of Science ®Google Scholar
• Kelly M. A., Shuaib A., Todd K. G. Matrix metalloproteinase activation and blood‐brain barrier breakdown following thrombolysis. Exp Neurol 2006; 200: 38–49
   PubMed Web of Science ®Google Scholar
• Xu Z., Zhao S., Zhou H., Ye H., Li J. Atorvastatin lowers plasma matrix metalloproteinase‐9 in patients with acute coronary syndrome. Clin Chem 2004; 50: 750–3
   PubMed Web of Science ®Google Scholar
• Manginas A., Bei E., Chaidaroglou A., Degiannis D., Koniavitou K., Voudris V., et al. Peripheral levels of matrix metalloproteinase‐9, interleukin‐6, and C‐reactive protein are elevated in patients with acute coronary syndromes: correlations with serum troponin I. Clin Cardiol 2005; 28: 182–6
   PubMed Web of Science ®Google Scholar
• Fukuda D., Shimada K., Tanaka A., Kusuyama T., Yamashita H., Ehara S., et al. Comparison of levels of serum matrix metalloproteinase‐9 in patients with acute myocardial infarction versus unstable angina pectoris versus stable angina pectoris. Am J Cardiol 2006; 97: 175–80
   PubMed Web of Science ®Google Scholar
• Suefuji H., Ogawa H., Yasue H., Kaikita K., Soejima H., Motoyama T., et al. Increased plasma tissue factor levels in acute myocardial infarction. Am Heart J 1997; 134: 253–9
   PubMed Web of Science ®Google Scholar
• Misumi K., Ogawa H., Yasue H., Soejima H., Suefuji H., Nishiyama K., et al. Comparison of plasma tissue factor levels in unstable and stable angina pectoris. Am J Cardiol 1998; 81: 22–6
   PubMed Web of Science ®Google Scholar
• Roldan V., Marin F., Fernandez P., Lujan J., Martinez J. G., Pineda J., et al. Tissue factor/tissue factor pathway inhibitor system and long‐term prognosis after acute myocardial infarction. Int J Cardiol 2001; 78: 115–9
   PubMed Web of Science ®Google Scholar
• Maly M., Vojacek J., Hrabos V., Kvasnicka J., Salaj P., Durdil V. Tissue factor, tissue factor pathway inhibitor and cytoadhesive molecules in patients with an acute coronary syndrome. Physiol Res 2003; 52: 719–28
   PubMed Web of Science ®Google Scholar
• Mallat Z., Benamer H., Hugel B., Benessiano J., Steg P. G., Freyssinet J. M., et al. Elevated levels of shed membrane microparticles with procoagulant potential in the peripheral circulating blood of patients with acute coronary syndromes. Circulation 2000; 101: 841–3
   PubMed Web of Science ®Google Scholar
• Chung N. A., Lydakis C., Belgore F., Li‐Saw‐Hee F. L., Blann A. D., Lip G. Y. Angiogenesis, thrombogenesis, endothelial dysfunction and angiographic severity of coronary artery disease. Heart 2003; 89: 1411–5
   PubMed Web of Science ®Google Scholar
• Lee K. W., Blann A. D., Lip G. Y. Inter‐relationships of indices of endothelial damage/dysfunction [circulating endothelial cells, von Willebrand factor and flow‐mediated dilatation] to tissue factor and interleukin‐6 in acute coronary syndromes. Int J Cardiol 2006; 111: 302–8
   PubMed Web of Science ®Google Scholar
• Falciani M., Gori A. M., Fedi S., Chiarugi L., Simonetti I., Dabizzi R. P., et al. Elevated tissue factor and tissue factor pathway inhibitor circulating levels in ischaemic heart disease patients. Thromb Haemost 1998; 79: 495–9
   PubMed Web of Science ®Google Scholar
• Soejima H., Ogawa H., Yasue H., Kaikita K., Nishiyama K., Misumi K., et al. Heightened tissue factor associated with tissue factor pathway inhibitor and prognosis in patients with unstable angina. Circulation 1999; 99: 2908–13
   PubMed Web of Science ®Google Scholar
• Lee K. W., Blann A. D., Lip G. Y. Plasma markers of endothelial damage/dysfunction, inflammation and thrombogenesis in relation to TIMI risk stratification in acute coronary syndromes. Thromb Haemost 2005; 94: 1077–83
   PubMed Web of Science ®Google Scholar
• Seljeflot I., Hurlen M., Hole T., Arnesen H. Soluble tissue factor as predictor of future events in patients with acute myocardial infarction. Thromb Res 2003; 111: 369–72
   PubMed Web of Science ®Google Scholar
• Vasan R. S. Biomarkers of cardiovascular disease: molecular basis and practical considerations. Circulation 2006; 113: 2335–62
   PubMed Web of Science ®Google Scholar